Zeruesenay Desta
Associate Professor of Medicine
Pharmacology and Toxicology
Department of Medicine/Division of Clinical Pharmacology
Indiana University School of Medicine
Name/email consistency: high
- Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo. Xu, C., Ogburn, E.T., Guo, Y., Desta, Z. Drug Metab. Dispos. (2012)
- Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. Desta, Z., Modak, A., Nguyen, P.D., Lemler, S.M., Kurogi, Y., Li, L., Flockhart, D.A. J. Pharmacol. Exp. Ther. (2009)
- Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., Flockhart, D.A., Zanger, U.M. Pharmacogenomics (2007)
- Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. Desta, Z., Ward, B.A., Soukhova, N.V., Flockhart, D.A. J. Pharmacol. Exp. Ther. (2004)
- The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Desta, Z., Wu, G.M., Morocho, A.M., Flockhart, D.A. Drug Metab. Dispos. (2002)
- In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin. Desta, Z., Soukhova, N., Flockhart, D.A. J. Clin. Psychopharmacol (2002)
